Lisaftoclax
Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively[1].
Product Specifications
CAS Number
[2180923-05-9]
Product Name Alternative
APG-2575; Bcl-2/Bcl-xl inhibitor 1
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bcl-2-bcl-xl-inhibitor-1.html
Purity
99.28
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(C1=CC=C(NC[C@@H]2OCCOC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC(CC5)=C(C6=CC=C(Cl)C=C6)CC75CCC7)CC4)C=C3OC8=CN=C(NC=C9)C9=C8
Molecular Formula
C45H48ClN7O8S
Molecular Weight
882.42
Precautions
H302, H315, H319
References & Citations
[1]WANG, Chia, et al. N- (PHENYLSULFONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS. Patent. WO2018027097A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Bcl-2; Bcl-xL
Available Sizes
Explore Other Products
Browse additional items from our catalog
Human Carboxyterminal propeptide of type III procollagen, PIIICP ELISA Kit
Human Carboxyterminal propeptide of type III procollagen, PIIICP ELISA Kit
Sox2 sgRNA CRISPR Lentivector (Mouse) (Target 3)